Chemotherapeutic targeting of myeloid-derived suppressor cells

Oncoimmunology. 2014 Jan 1;3(1):e27359. doi: 10.4161/onci.27359.

Abstract

Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

Keywords: ROS; cancer; chemoimmunomodulation; doxorubicin; helper T lymphocytes; myeloid-derived suppressor cells.

Publication types

  • Research Support, N.I.H., Extramural